Lazcluze lazertinib

Drug Class

EGFR tyrosine kinase inhibitor

Mechanism

Inhibits EGFR tyrosine kinase activity, targeting both activating EGFR mutations (exon 19 deletion and L858R) and resistance mutations (T790M).

Approved Indication

In combination with amivantamab for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations, per its FDA approval.

What This Means For Patients

Lazcluze is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2024) — Sources

Pivotal Clinical Evidence

• MARIPOSA — Yang et al., N Engl J Med 2025 (NCT04487080) — Sources

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-lazertinib-egfr-mutated-advanced-nsclc
• https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218268